AlphaMark Advisors LLC raised its stake in United Therapeutics Co. (NASDAQ:UTHR) by 73,612.0% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 36,856 shares of the biotechnology company’s stock after buying an additional 36,806 shares during the period. United Therapeutics makes up about 1.8% of AlphaMark Advisors LLC’s investment portfolio, making the stock its 14th largest holding. AlphaMark Advisors LLC owned approximately 0.08% of United Therapeutics worth $4,141,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Bank of Montreal Can raised its stake in United Therapeutics by 53.3% during the 4th quarter. Bank of Montreal Can now owns 107,039 shares of the biotechnology company’s stock valued at $15,836,000 after purchasing an additional 37,207 shares during the period. Creative Planning raised its stake in United Therapeutics by 19.4% during the 4th quarter. Creative Planning now owns 6,301 shares of the biotechnology company’s stock valued at $932,000 after purchasing an additional 1,023 shares during the period. Schwab Charles Investment Management Inc. raised its stake in United Therapeutics by 5.5% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 158,271 shares of the biotechnology company’s stock valued at $23,417,000 after purchasing an additional 8,243 shares during the period. Acadian Asset Management LLC raised its stake in United Therapeutics by 2.4% during the 4th quarter. Acadian Asset Management LLC now owns 1,121,068 shares of the biotechnology company’s stock valued at $165,861,000 after purchasing an additional 26,122 shares during the period. Finally, State of Alaska Department of Revenue acquired a new stake in United Therapeutics during the 4th quarter valued at $384,000.
Several analysts have issued reports on UTHR shares. BidaskClub downgraded shares of United Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, May 1st. Credit Suisse Group reissued an “underperform” rating and set a $118.00 target price on shares of United Therapeutics in a research note on Thursday, January 18th. Barclays restated an “underweight” rating and set a $105.00 price target (down from $115.00) on shares of United Therapeutics in a report on Thursday, February 22nd. Finally, ValuEngine cut shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, February 2nd. Four investment analysts have rated the stock with a sell rating, four have assigned a hold rating and three have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $134.00.
United Therapeutics stock opened at $107.70 on Friday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 4.81 and a current ratio of 5.13. United Therapeutics Co. has a 12 month low of $106.65 and a 12 month high of $109.42. The firm has a market cap of $4.66 billion, a PE ratio of 9.89, a P/E/G ratio of 27.37 and a beta of 1.33.
United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, May 2nd. The biotechnology company reported $5.57 EPS for the quarter, beating the consensus estimate of $3.62 by $1.95. United Therapeutics had a net margin of 27.74% and a return on equity of 26.68%. The business had revenue of $389.20 million for the quarter, compared to analysts’ expectations of $393.96 million. During the same period in the previous year, the company posted $3.61 EPS. United Therapeutics’s revenue was up 5.0% on a year-over-year basis. equities analysts expect that United Therapeutics Co. will post 13.04 earnings per share for the current fiscal year.
United Therapeutics Profile
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR).
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.